Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A liquid formulation of a therapeutic agent comprising:

rapamycin in a pharmaceutically effective dosage; ~~and~~

~~one or more pharmaceutically acceptable solubility enhancers~~ ethanol in a concentration of less than two percent;

polyethylene glycol; and

water.

2. (Cancelled) The liquid formulation according to claim 1, further comprising one or more pharmaceutically acceptable stabilizers.

3. (Currently Amended) The liquid formulation according to claim ~~2~~1, wherein the concentration of rapamycin in solution is in the range from about 1 mg/ml to about 15 mg/ml.

4. (Original) The liquid formulation according to claim 3, wherein the rapamycin comprises sirolimus.

5. (Original) The liquid formulation according to claim 3, wherein the rapamycin comprises CCI-779.

6. (Cancelled) The liquid formulation according to claim 2, wherein the one or more pharmaceutically acceptable stabilizer and solubility enhancers comprises polyethylene glycol.

7. (Currently Amended) The liquid formulation according to claim ~~2~~1, ~~wherein the one or more pharmaceutically acceptable stabilizer and solubility enhancers~~ further ~~comprises~~ comprising Vitamin E TPGS.

8. (Cancelled) The liquid formulation according to claim 1, further comprising water.

9. (Withdrawn) A method for the treatment of vascular disease comprising the administration of a liquid formulation of rapamycin proximate the disease site.

10. (Withdrawn) The method for the treatment of vascular disease according to claim 9, wherein the liquid formulation of rapamycin comprises rapamycin in a pharmaceutically effective dosage and one or more pharmaceutically acceptable solubility enhancers.